Skip to main content
AAN.com
Editorial
April 11, 2017
Open Access

Foveal thinning in neuromyelitis optica
A sign of retinal astrocytopathy?

Patients with neuromyelitis optica spectrum disorder (NMOSD) typically manifest recurrent episodes of optic neuritis (ON) and myelitis. Recently revised diagnostic criteria1 do not restrict the diagnosis of NMOSD to patients associated with elevation of anti–aquaporin 4 antibody (AQP4Ab), capable of causing destruction of astrocytes expressing AQP4. If compatible clinical and radiologic features are present, the diagnosis of NMOSD is given to patients with autoantibodies (Ab) specific for myelin oligodendrocyte glycoprotein (MOG).2 However, compared with MOGAb+ NMOSD, clinical relapses tend to be more serious in AQP4Ab+ patients and could result in devastating neurologic sequelae manifested by blindness, paralysis, cognitive dysfunction, or neurogenic pain.
While acute relapses are characteristic of the relapsing-remitting form of MS, insidious worsening related to chronic neuroinflammation is the basis for the diagnosis of secondary progressive MS. Although secondary progressive disease was assumed to be uncommon in NMOSD,3 recent studies relying on MRI findings have described progressive brain or spinal cord atrophy4,5 without a sign of relapses in patients with AQP4Ab+ NMOSD.
In this issue of Neurology® Neuroimmunology & Neuroinflammation, Oertel et al.6 measured the foveal thickness and the thickness of surrounding structures (peripapillary retinal nerve fiber layer and ganglion cell and inner plexiform layers) in patients with NMOSD using optical coherence tomography (OCT). They compared eyes from patients who had long extensive spinal cord lesions archetypal for NMOSD but no history of ON with eyes from NMOSD patients with history of ON and eyes from healthy controls. In parallel, diffusion tensor imaging (DTI) was used to evaluate the microstructural changes in the optic radiation, which is responsible for transmitting visual signals from the retina to the visual cortex. The authors demonstrate that central foveal thickness is significantly reduced in the eyes of the 6 patients without a history of ON as compared to controls, although high-contrast visual acuity of these patients was normal. Fovea is a tiny pit in the macula of the retina and is responsible for the central, high-resolution color vision. As the fovea is enriched in Müller cells expressing AQP4, their observation suggests the occurrence of primary retinal astrocytopathy in NMOSD. DTI analysis also showed secondary microstructural changes in the afferent visual system in parallel with the foveal thinning. Shortly before this publication,6 OCT was applied by Korean and Japanese groups for the analysis of retinal changes in patients with NMOSD.7,8 Notably, the Korean study also showed the presence of foveal thinning in the retina of unaffected eyes of patients with NMOSD. Moreover, the foveal thinning was correlated with a reduction in low-contrast visual acuity in the Korean study, implying that the retina of the “unaffected eyes” in AQP4Ab+ NMOSD might be actually damaged by chronic autoimmune inflammation targeting Müller cells or retinal astrocytes.
One could say that prevention of relapses is a goal of therapy for NMOSD, assuming that only serious relapses are thought to cause neurologic sequelae. However, the presence of retinal changes without previous ON indicates that an insidious development of pathology cannot be ignored in patients with NMOSD. Given that the life expectancy of patients with NMOSD has substantially improved, the future goal of therapy should not only be prevention of relapses, but prevention of new lesion development by immunotherapy under close monitoring. Alterations in Müller cells have been also described in a rodent model of NMOSD.9 This pathology was dependent on both AQP4Ab and T cells, indicating the importance of T-cell control to achieve good control of NMOSD.
It is known that the shape and size of retinal fovea evaluated by OCT differ among different ethnic groups. In this regard, data from both Caucasian and Asian patients are precious and useful. The size of the avascular area in the fovea may influence OCT evaluation.10 Therefore, future studies should evaluate the avascular area as well.
The study by Oertel et al.6 together with recent publications from other investigators7,8 have begun to stimulate discussion about the goal of therapy in patients with NMOSD regarding the prognosis of visual function. However, it is too early to make any conclusion until the reproducibility of the results is confirmed in prospective studies involving more patients.

Footnote

REFERENCES

1.
Wingerchuk D, Banwell B, Bennett J, et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology 2015;85:177–189.
2.
Ikeda K, Kiyota N, Kuroda H, et al. Severe demyelination but no astrocytopathy in clinically definite neuromyelitis optica with anti-myelin-oligodendrocyte glycoprotein antibody. Mult Scler 2015;21:656–659.
3.
Wingerchuk DM, Pittock SJ, Lucchinetti CF, et al. A secondary progressive clinical course is uncommon in neuromyelitis optica. Neurology 2007;68:603–605.
4.
Warabi Y, Takahashi T, Isozaki E. Progressive cerebral atrophy in neuromyelitis optica. Mult Scler 2015;21:1872–1875.
5.
Ventura RE, Kister I, Chung S, et al. Cervical spinal cord atrophy in NMOSD without a history of myeitis or MRI-visible lesions. Neurol Neuroimmunol Neuroinflamm 2016;3:e224. doi: 10.1212/NXI.0000000000000224.
6.
Oertel F, Kuchling J, Zimmermann H, et al. Microstructural visual system changes in AQP4-antibody–seropositive NMOSD. Neurol Neuroimmunol Neuroinflamm 2017;4:e334. doi: 10.1212/NXI.0000000000000334.
7.
Jeong IH, Kim HJ, Kim NH, Jeong KS, Park CY. Subclinical primary retinal pathology in neuromyelitis optica spectrum disorder. J Neurol 2016;263:1343–1348.
8.
Matsumoto Y, Mori S, Ueda K, et al. Impact of the anti-aquaporin-4 autoantibody on inner retinal structure, function and structure-function associations in Japanese patients with optic neuritis. PLoS One 2017;12:e0171880.
9.
Zeka B, Hastermann M, Kaufmann N, et al. Aquaporin 4-specific T cells and NMO-IgG cause primary retinal damage in experimental NMO/SD. Acta Neuropathol Commun 2016;4:82.
10.
Tick S, Rossant F, Ghorbel I, et al. Foveal shape and structure in a normal population. Invest Ophthalm Vis Sci 2011;52:5105–5110.

Information & Authors

Information

Published In

Neurology® Neuroimmunology & Neuroinflammation
Volume 4Number 3May 2017
PubMed: 28439528

Publication History

Published online: April 11, 2017
Published in print: May 2017

Permissions

Request permissions for this article.

Disclosure

T. Yamamura served on the scientific advisory board for Biogen Japan, Chugai Pharmaceutical Co, and Takeda Pharmaceutical Company; received travel funding and/or speaker honoraria from Novartis, Nihon, Santen, Abbott Japan/Eisai, Biogen Japan, Dainippon Sumitomo, Bayer Holding, and Astellas Pharma Inc Takeda; and received research support from Ono, Chugai, Teva, Mitsubishi Tanabe Pharma, Asahi Kuraray Medical, and Ministry of Health, Labour, and Welfare of Japan. I. Nakashima received travel funding and speaker honoraria from Mitsubishi Tanabe Pharma and Novartis; is an editorial board member for Multiple Sclerosis International; and received grant support from LKI Medicine Corporation. Go to Neurology.org/nn for full disclosure forms.

Study Funding

No targeted funding reported.

Authors

Affiliations & Disclosures

Takashi Yamamura, MD, PhD
From the National Institute of Neuroscience (T.Y.), NCNP, Kodaira, Tokyo; and Department of Neurology (I.N.), Tohoku University School of Medicine, Aoba-ku, Sendai, Japan.
Disclosure
Scientific Advisory Boards:
1.
(1)Biogen Japan (2) Chugai Pharmaceutical Co., Ltd (3) Takeda Pharamaceutical Co.
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
(1) Novartis Pharma (2) Nihon Pharmaceutical Co., Ltd., (3) Santen Pharmaceutical Co., Ltd., (4) Abbott Japan Co., Ltd./Eisai Co., Ltd., (5) Biogen Japan, (6) Dainippon Sumitomo Pharma Co., Ltd., (7) Bayer Holding Ltd., (8) Astellas Pharma Inc. (9) Takeda Pharamaceutical Co.
Editorial Boards:
1.
Clinical and Experimental Neuroimmunology, Editor, since 2010
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
(1) Ono Pharmaceutical Co., Ltd., (2) Chugai Pharmaceutical Co., Ltd., (3) Teva Pharmaceutical K.K., (4) Mitsubishi Tanabe Pharma Corporation, (5) Asahi Kasei Kuraray Medical CO., Ltd.
Research Support, Government Entities:
1.
(1) Ministry of Health, Labour and Welfare of Japan, the Health and Labour Sciences Research Grants on Intractable Diseases (Neuroimmunological Diseases), investigator, since 2010.
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Ichiro Nakashima, MD, PhD
From the National Institute of Neuroscience (T.Y.), NCNP, Kodaira, Tokyo; and Department of Neurology (I.N.), Tohoku University School of Medicine, Aoba-ku, Sendai, Japan.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
Received funding for a trip and speaks from Mitsubishi Tanabe Pharma (2012-2016) and Novartis Pharma (2012-2015).
Editorial Boards:
1.
Served as an editorial board member of Multiple Sclerosis International(2010-present).
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
Received grant support from LSI Medience Corporation (2012-2016).
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE

Notes

Correspondence to Dr. Yamamura: [email protected]
Funding information and disclosures are provided at the end of the editorial. Go to Neurology.org/nn for full disclosure forms. The Article Processing Charge was funded by Neurology: Neuroimmunology & Neuroinflammation.

Metrics & Citations

Metrics

Citation information is sourced from Crossref Cited-by service.

Citations

Download Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Select your manager software from the list below and click Download.

Cited By
  1. Retinal Changes in Double-Antibody Seronegative Neuromyelitis Optica Spectrum Disorders, Neurology Neuroimmunology & Neuroinflammation, 11, 5, (2024)./doi/10.1212/NXI.0000000000200273
    Abstract
  2. Prevalence, Demographic, and Clinical Factors Associated With Cognitive Dysfunction in Patients With Neuromyelitis Optica Spectrum Disorder, Neurology, 102, 1, (2023)./doi/10.1212/WNL.0000000000207965
    Abstract
  3. Progress in treatment of neuromyelitis optica spectrum disorders (NMOSD): Novel insights into therapeutic possibilities in NMOSD, CNS Neuroscience & Therapeutics, 28, 7, (981-991), (2022).https://doi.org/10.1111/cns.13836
    Crossref
  4. Comparisons of clinical phenotype, radiological and laboratory features, and therapy of neuromyelitis optica spectrum disorder by regions: update and challenges, Autoimmunity Reviews, 21, 1, (102921), (2022).https://doi.org/10.1016/j.autrev.2021.102921
    Crossref
  5. Differential patterns of parafoveal and peripapillary vessel density in multiple sclerosis and neuromyelitis optica spectrum disorder, Multiple Sclerosis and Related Disorders, 49, (102780), (2021).https://doi.org/10.1016/j.msard.2021.102780
    Crossref
  6. AQP4-IgG and MOG-IgG Related Optic Neuritis—Prevalence, Optical Coherence Tomography Findings, and Visual Outcomes: A Systematic Review and Meta-Analysis, Frontiers in Neurology, 11, (2020).https://doi.org/10.3389/fneur.2020.540156
    Crossref
  7. Pain in NMOSD and MOGAD: A Systematic Literature Review of Pathophysiology, Symptoms, and Current Treatment Strategies, Frontiers in Neurology, 11, (2020).https://doi.org/10.3389/fneur.2020.00778
    Crossref
  8. Visualizing the Central Nervous System: Imaging Tools for Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorders, Frontiers in Neurology, 11, (2020).https://doi.org/10.3389/fneur.2020.00450
    Crossref
  9. Altered fovea in AQP4-IgG–seropositive neuromyelitis optica spectrum disorders, Neurology Neuroimmunology & Neuroinflammation, 7, 5, (2020)./doi/10.1212/NXI.0000000000000805
    Abstract
  10. Cohort profile: a collaborative multicentre study of retinal optical coherence tomography in 539 patients with neuromyelitis optica spectrum disorders (CROCTINO), BMJ Open, 10, 10, (e035397), (2020).https://doi.org/10.1136/bmjopen-2019-035397
    Crossref
  11. See more
Loading...

View Options

View options

PDF and All Supplements

Download PDF and Supplementary Material

Full Text

View Full Text
Login options

Check if you have access through your login credentials or your institution to get full access on this article.

Personal login Institutional Login
Purchase Options

The neurology.org payment platform is currently offline. Our technical team is working as quickly as possible to restore service.

If you need immediate support or to place an order, please call or email customer service:

  • 1-800-638-3030 for U.S. customers - 8:30 - 7 pm ET (M-F)
  • 1-301-223-2300 for customers outside the U.S. - 8:30 - 7 pm ET (M-F)
  • [email protected]

We appreciate your patience during this time and apologize for any inconvenience.

Media

Figures

Other

Tables

Share

Share

Share article link

Share